214 related articles for article (PubMed ID: 33191086)
21. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
Yin C; Jia S; Yang X; Wu L
Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
[TBL] [Abstract][Full Text] [Related]
22. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
[TBL] [Abstract][Full Text] [Related]
23. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Thieno[2,3-
Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents.
Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D
Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080
[TBL] [Abstract][Full Text] [Related]
27. The design, synthesis and cellular imaging of a tumor-anchored, potent and cell-permeable BRD4-targeted fluorescent ligands.
Zhang H; Zhang M; Zheng YC; Zhang JG; Xu H
Bioorg Chem; 2021 Sep; 114():105120. PubMed ID: 34216895
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
29. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
[TBL] [Abstract][Full Text] [Related]
30. Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC).
Li Z; Ma S; Yang X; Zhang L; Liang D; Dong G; Du L; Lv Z; Li M
Eur J Med Chem; 2021 Oct; 222():113608. PubMed ID: 34119833
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of novel 2,3-dihydrochromeno[3,4-d]imidazol-4(1H)-one derivatives as potent anticancer cell proliferation and migration agents.
Han X; Luo J; Wu F; Hou X; Yan G; Zhou M; Zhang M; Pu C; Li R
Eur J Med Chem; 2016 May; 114():232-43. PubMed ID: 26994691
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of coumarin derivatives as potential BRD4 inhibitors.
Cui QH; Li WB; Wang ZY; Xu KY; Wang S; Shi JT; Zhang LW; Chen SW
Bioorg Chem; 2022 Nov; 128():106117. PubMed ID: 36063752
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents.
Li L; Quan D; Chen J; Ding J; Zhao J; Lv L; Chen J
Eur J Med Chem; 2019 Dec; 184():111732. PubMed ID: 31610372
[TBL] [Abstract][Full Text] [Related]
36. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
Zhang J; Tang P; Zou L; Zhang J; Chen J; Yang C; He G; Liu B; Liu J; Chiang CM; Wang G; Ye T; Ouyang L
J Med Chem; 2021 Dec; 64(24):18025-18053. PubMed ID: 34908415
[TBL] [Abstract][Full Text] [Related]
38. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
[No Abstract] [Full Text] [Related]
39. Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells.
He ZX; Huo JL; Gong YP; An Q; Zhang X; Qiao H; Yang FF; Zhang XH; Jiao LM; Liu HM; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 210():112970. PubMed ID: 33153765
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors.
Xu KY; Wang XT; Cheng L; Cui QH; Shi JT; Zhang LW; Chen SW
Bioorg Med Chem; 2023 Jan; 78():117152. PubMed ID: 36599264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
